NCT02314637View on ClinicalTrials.gov

Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Teneligliptin

Teneligliptin for 52 weeks

DRUG

Teneligliptin + Sulfonylurea

Teneligliptin for 52 weeks in combination with sulfonylurea

Trial Locations (1)

Unknown

Reserch site, Shikoku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY